Abstract. The underlying etiological cause of non-hereditary colorectal cancer has yet to be determined. The adenomacarcinoma sequence is widely accepted, however, a sole trigger has not been specified. Therefore, we sought to further define genotypic and phenotypic parameters that could be involved in promoting a possible infection, inflammation and hyper proliferation, followed by the adenoma-carcinoma sequence. Expression of phenotype-related parameters for MHC class I (HLA-A N-20 and β2 microglobulin) and class II (HLA-DRα and HLA-DR) as well as CD45 and carcinoembryonic antigen (CEA) were investigated immunohistochemically in a series of 93 colorectal cancers. Additionally, in 49 of the tumours the MHC class II genotype was analysed. MHC class II genotype analyses revealed a tendency towards DRB1 * 08 and DQB1 * 04. A significant association among the MHC class I markers or the MHC class II markers was found. No difference in marker expression could be detected between tumour and stromal tissue, however a significant inverse expression existed for markers of the functionally different class I or II systems. With the exception of CEA, there was no correlation between expression of any marker and tumour grade. Only 2% of tumours expressed no markers for MHC class I and II. Further studies on MHC class I and II genotype and phenotype relation in colorectal cancer may help to identify trigger mechanisms for tumourigenesis, involved markers and possible mechanisms of subsequent immune escape.
Introduction
The adenoma-carcinoma sequence has been widely accepted in the development of sporadic colorectal carcinoma (1) . In addition, low adiponectin levels and high insulin levels have recently been linked to a higher incidence of colorectal carcinoma and may, therefore, provide the metabolic background for this sequence (2, 3) . However, the initial trigger has yet to be defined.
Inflammation of the intestinal mucosa could be part of such a triggering mechanism. Indeed, inflammatory bowel diseases have a higher incidence of colorectal cancer and, therefore, more strict regimens of surveillance have been incorporated in recent guidelines (4) (5) (6) . A genetic predisposition in chronic inflammatory bowel diseases has been found and linked to genes related to inflammation and the immune response (7) . Inflammation and immune response involve molecules of antigen processing, presentation and cellular and cytokine mediated interaction with or among cells of the immune system (8) . As such, among major risk factors in Crohn's disease are mutations in NOD2 and Atg16L1, both resulting in defective macroautophagy and subsequent MHC class II presentation with ineffective CD4 T-cell response (9, 10) . Indeed, the expression of inflammatory genes including MHC class II genes even in sporadic adenocarcinoma has been found to be associated with poor prognosis (11) .
The MHC system plays a key role in antigen processing, presentation and cellular interaction. Even an MHC restriction to certain genotypes has been suggested in tumours like melanoma, tumours of the stomach, the liver, the prostate, the ovary, thyroid gland, the lungs, but also some types of leukaemia or lymphoma (1235). However, the link to the MHC system is not unequivocal in these tumours. Contrary to that, the prevalence of DQB1 and DRB1 * 03 has been proven to cause an altered response to the human papillomavirus in the cervix. Here, these MHC class II types allow for an infection with HPV 16, 18, 31 or 33, which leads to cellular overexpression of viral oncogenes such as E5, E6 and E7. As a result, PDGFreceptors will be constitutively active, the p53-tumour suppressor gene product is inactivated by ubiquitination and binding to pRB with subsequent release of E2F1 and Sphase progression, all together processes, that allow for the development of tumour (20, 36, 37) .
The link between the MHC system and tumour formation in sporadic colorectal cancers has up to now not been conclusively explained. Older data could not demonstrate a link between MHC expression and colorectal cancer (38 The reaction was visualised using the avidin-biotin staining method according to the catalysed signal amplification (CSA) system with AEC or DAB chromogen (Immunotech, Hamburg, Germany). Slides were counterstained with haematoxylin, rinsed in water and mounted in glycerol gelatine (SigmaAldrich, Munich, Germany).
Staining was than evaluated by counting stained cells per 100 and grouping into 0; 1, 1-5; 2, 6-25; 3, 26-50; 4, 51-75; 5, 76-100 cells and estimating the intensity of staining (from 0 missing to 3 very strong). The product of both (ratio and intensity) has been referred to as the SI (staining index) and was used for further analyses. CD45 staining was evaluated by counting stained cells per 100 and grouping into 0; 1, 1-10; 2, 11-50, 3, >50 cells without estimating the intensity of staining. Evaluation was conducted for tumourous and stromal tissue separately.
DNA extraction. DNA extraction was carried out as previously described (43) . In brief, deparaffinised sections were airdried and incubated in 1 M guanidium thiocyanate overnight at room temperature, washed in TE and proteinase Kdigested for 72 h at 55˚C. After centrifugation the supernatant was phenol and chloroform extracted.
HLA genotype determination. Low resolution HLA-genotyping of genomic DNA was carried out using the Amplicor HLA DRB test according to the suppliers' instructions (Dynal, Hamburg, Germany) for the DRB1 * and DQB1 * loci.
Statistical analyses. Statistical analyses were performed with SPSS software using the Z max test (46) Statistical analyses of HLA phenotype-related parameters were performed with the Prism GraphPad software (GraphPad Software Inc., La Jolla, CA, USA) using the two-tailed unpaired ttest or the Ftest of variances to evaluate tumour characteristics and immunohistochemistry data. Results were considered statistically significant if P<0.05. Evaluations were carried out to compare tumourous and stromal tissue. Furthermore, tissues were grouped according to low and high SI of a marker, i.e., non or almost nonmarker expressing and higher marker expressing tumours. The resulting pairs of a further marker were subsequently assessed for differences. A cutoff value of ≤2 was taken to distinguish between non or almost nonmarker expressing and higher marker expressing tumours. This cut-off was used in all subsequent analyses.
Results
Tumour characteristics. Patient and tumour characteristics are summarised in Table I .
Immunohistochemistry and phenotype assessment. Paraffin sections of tumours were immunostained against CEA to visualize the malignant cells, against CD45 to detect infiltrating leucocytes, and against HLA-DRα chain and HLA-DR for MHC class II, as well as HLAA and β2 microglobulin for MHC class I (Fig. 1 ). There was no CEA expression in 3.7% of the tumours and 2.0% of tumours did not express any detectable markers of MHC class I or II. A significant albeit small difference could be proven for tumour grade and expression of CEA indicating that tumours with higher grade and with lower differentiation expressed less CEA (Fig. 2) .
MHC class I and II marker expression in tumours and stroma. Expression of MHC related markers was compared between tumour cells and stromal tissue. The only difference between tumourous tissue and stromal tissue was found for CD45. Tumourous tissue exhibited a lower SI and herewith lower content of intermingled leucocytes than the surrounding stroma (P<0.0001, Fig. 3 ). No differences in the relative expression between tumour and stromal tissue were found for the markers HLADRα chain, HLA-DR, HLA-A and β2 microglobulin (Fig. 4) . However, HLAA expression was not detectable in 31% of the tumours and was low in another 38% of the tumours.
On the contrary, the comparison of SI between tumourous and stromal tissue revealed a significant correlation after grouping according to lower and higher SI, in that the low SI in the stromal tissue correlated with the low expression in the tumourous tissue (and vice versa) for the MHC class II markers HLADRα chain (P<0.002) and HLADR (P<0.0001) and for the MHC class I markers HLAA (P<0.0001) and β2 microglobulin (P<0.0001, Fig. 5 ).
Inverse expression of MHC class I and II markers.
The MHC class II marker HLADR was not uniformly expressed in tumourous tissues. A low expression in the tumour correlated with a low expression of HLA-DR in the stroma. However, the lower SI of the MHC class II marker HLADR in the tumour correlated with an inversely higher stromal SI of the MHC class I marker HLAA (P=0.03) and β2 microglobulin and vice versa. A similar inverse staining pattern could be observed, when tumours were grouped according to a low vs. high staining index of stromal HLA-DR. A low stromal expression of this MHC class II marker correlated with a higher expression of the MHC class I markers HLAA (P= 0.02) and β2 microglobulin (P=0.06) in the stroma, but also in the tumours. The expression of the MHC class II marker HLADRα chain was similar to HLA-DR in that a low expression in the tumour correlated with a low expression of HLA-DR in the stroma. The expression pattern did not reach significance when compared with any of the other markers (data not shown).
The expression of the MHC class I marker HLAA in tumour cells significantly correlated with β2 microglobulin, i.e., a lower HLA-A expression was accompanied by a lower β2 microglobulin expression (P= 0.0003). In the group with lower tumour SI for HLA-A there was a inversely higher stromal HLADR SI (P= 0.007) as in tissues with higher HLAA SI, while there was a positive correlation with the stromal MHC class I markers HLAA (P= 0.0001) and β2 microglobulin (P= 0.0002). Grouping for low vs. high stromal HLAA SI demonstrated, that a low expression in the stroma correlated with a low expression of tumour HLAA, stromal (P= 0.005) and tumour β2 microglobulin (P=0.002) and with an inversely higher stromal HLADR (P=0.04).
Grouping for low vs. high tumour β2 microglobulin SI showed that a low expression in the tumours correlated with a low HLAA expression within the tumour (P=0.0002) but also a low expression of β2 microglobulin (P<0.0001) and HLAA in the stroma (P= 0.0037), which was accompanied by an inversely higher HLADR expression in the stroma (P=0.018, Fig. 6 ). , and *** indicate highly significant differences (P<0.002 and P<0.0001, respectively). , and *** indicate (highly) significant differences (P= 0.018, P= 0.0037, and P<0.0002, respectively).
Determination

Discussion
In the study presented, we sought to analyse immunological features of MHC class I and II as a possible prerequisite of inflammation and inflammatory response and eventually neoplastic degeneration in sporadic colorectal carcinoma. We found a wide inter-and intra-tumour variation in the proportional expression of MHC class I and II markers and of leucocyte infiltration according to common leucocyte antigen expression.
The immunohistochemical analyses suggests a similar expression level of the investigated markers in tumours and stromal tissue. This finding is in accordance with former data on microdissection (45) . However, microarray data are not unequivocal and, hence, still a matter of debate. The similar expression patterns of the investigated markers in tumours and stromal tissue might characterise the microenvironment in a given tumour as a 'functional unit' of stromal and tumourous tissue with respect to the immunological behaviour. However, completely different expression patterns have been reported for metabolic features in tumour and stromal cells, which also let investigators to hypothesise of a functional unit of the highly metabolising and growing tumour cells and their fostering stromal bystander cells (46) . Contrary to former reports we found a correlation between β2 microglobulin and the MHC class I marker expression (47) . In the normal cell β2 microglobulin associates with the α chain of MHC class I molecules and with class Ilike molecules such as CD1 or Qa. This association is necessary for the cell surface expression of MHC class I and the stability of the peptide binding groove. Indeed, if β2 microglobulin is lacking, only very limited amounts of MHC class I molecules can be detected on the cell surface as has been shown in β2 microglobulin knockout mice. In the absence of MHC class I, development CD8 T cells development is hampered which results in an impairment of acquired immunity. In fact, β2 microglobulin knockout mice have been used in cell transplant studies because of the excellent engraftment in these immunedeficient hosts (48, 49) . This could translate into a diminished immunological response to a developing tumour and its antigens.
The expression of HLA-A and β2 microglobulin as markers and surrogate markers for MHC class I was in general low in our study. HLAA expression was not detectable in 31% of tumours and was low in another 38% of tumours. Similar results have been reported by others (50) and attributed to a possible mechanism of tumour escape from immune surveillance as discussed above. Although this concept is intriguing and seeks to explain an uncontrolled tumour growth in spite of an apparent normal immune system this concept does not provide an explanation as to why an immune reaction against the own cells, even if tumourous, should exist. Still, it may be possible, that tumour and stromal tissue do behave similarly but differently in terms of their immunological responses compared to other tissues not affected by tumour growth.
Our results show an inverse expression of I and II markers which cannot be easily explained. The principal function of MHC class II molecules includes the processing and subsequent presentation of external antigens to immunocompetent T-helper cells. This involvement of MHC class II, the TCR complex and CD4 molecules in the control and regulation of T-helper lymphocytes is well understood (51, 52) . The presentation of external antigens via MHC class II can induce either stimulation of immunological response or its blunting via apoptosis (53, 54) . However, it was noted that MHC class II molecules not only present external antigens but can also present cytosolic and nuclear antigens. This process involves macroautophagy and chaperone-mediated autophagy (55, 56) . It could result in cross-presentation of viral antigens as well as of tumour-related or even self antigens. Indeed, analyses of the MHC class II ligandome demonstrated the presentation of up to 30% self antigens (57) . The implication with respect to the tumour is as yet to be determined, but could offer further explanation for the possible immune escape of colorectal cancer. Of note, macroautophagy-related MHC class II presentation of MUC1-derived peptides by dendritic cells significantly inhibited MUC1specific CD4 cell proliferation (58) . As to whether an expression of MHC class II molecules could also be a hint for the involvement of an infectious trigger, cannot be concluded from the data presented. Also, the infection with a specific pathogen could trigger the expression of MHC class II molecules. Moreover, it is intriguing to hypothesise a situation similar to that demonstrated in cervix carcinoma subsequent to the infection with the human papillomavirus. In the cervix carcinoma a specific HLA type enhances the infection with the human papillomavirus. Therefore, we sought to identify the HLA type of the MHC class II locus by low resolution HLA-genotyping. However, although some differences can be seen, a single prevailing HLA type could not be determined due to the small number of cases. Therefore, we fail to demonstrate a link between the HLA system and the sporadic colorectal carcinoma.
In summary we found a similar immunological marker expression in tumour and stromal tissue, which we interpret as a similar functional difference with respect to the immune system or immunogenicity. Second, we confirmed an absent or decreased expression of MHC class I markers in sporadic colon carcinoma. This lacking MHC class I expression results in the loss or at least decreased antigen presentation. Therefore, a blunted immunological response can be hypothesised. Third, we found an inverse expression of MHC class I and II markers. To date it is not clear as to whether this constitutes a true hint of the involvement of an external pathogen in the induction of the process of transformation. Further studies on MHC class I and II genotype and phenotype relation in colorectal cancer are necessary and may help to identify triggering mechanisms of tumourigenesis, involved markers and possible subsequent immune escape.
